董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Omid Farokhzad | 男 | Chief Executive Officer and Chair of the Board | 56 | 75.11万美元 | 未持股 | 2025-09-02 |
| Terrance McGuire | 男 | Director | 68 | 未披露 | 未持股 | 2025-09-02 |
| Nicolas Roelofs | 男 | Lead Independent Director | 67 | 未披露 | 未持股 | 2025-09-02 |
| Meeta Gulyani | 女 | Director | 56 | 未披露 | 未持股 | 2025-09-02 |
| Isaac Ro | 男 | Director | -- | 未披露 | 未持股 | 2025-09-02 |
| Dipchand Nishar | 男 | Director | 56 | 未披露 | 未持股 | 2025-09-02 |
| David Hallal | 男 | Director | 58 | 未披露 | 未持股 | 2025-09-02 |
| Robert Langer | 男 | Director | 76 | 未披露 | 未持股 | 2025-09-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Omid Farokhzad | 男 | Chief Executive Officer and Chair of the Board | 56 | 75.11万美元 | 未持股 | 2025-09-02 |
| David R. Horn | 男 | President, Chief Financial Officer and Treasurer | 58 | 未披露 | 未持股 | 2025-09-02 |
董事简历
中英对照 | 中文 | 英文- Omid Farokhzad
-
Omid Farokhzad，自Senti Biosciences，Inc.业务合并于2022年6月结束以来，一直担任Senti Biosciences，Inc.董事会成员。他于2017年创立了推进变革性蛋白质组学平台的Seer, Inc.（纳斯达克：SEER），并自2018年2月起担任其首席执行官，自2017年3月起担任其董事会成员，自2020年9月起担任主席。他还曾于2021年3月至2022年6月担任Senti Biosciences，Inc.前身Dynamics Special Purpose Corp.（纳斯达克股票代码：DYNS）的创始人、首席执行官兼主席。他此前与人共同创立了BIND Therapeutics（已被辉瑞公司（NYSE：PFE）收购）、Selecta Biosciences, Inc.（纳斯达克：SELB），以及Tarveda Therapeutics，Inc.，一家私营肿瘤生物治疗公司，后者正在开发用于生物制剂和基因治疗的新型抗原特异性耐受平台。2004年9月至2018年2月，任哈佛医学院教授，布莱根妇女医院纳米医学中心主任。Farokhzad博士拥有波士顿大学的硕士和医学博士学位，以及麻省理工学院斯隆管理学院的MBA学位。
Omid Farokhzad,has served as Chief Executive Officer since February 2018, and as a member of board of directors since March 2017, serving as the Chair since September 2020, and as President of the Company from September 2022 until November 2023. He served as the executive chair of Dynamics Special Purpose Corp., a blank check company, from May 2021 until June 2022. From September 2004 to February 2018, he was a Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women's Hospital. He previously co-founded BIND Therapeutics, a biotechnology company acquired by Pfizer Inc., Selecta Biosciences, Inc., a clinical-stage biotechnology company, and Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company. He currently serves as a member of the board of directors of several privately-held companies and previously served as a director of Senti Biosciences, Selecta Biosciences and BIND Therapeutics. He holds an M.A. and M.D. from Boston University and an M.B.A. from Massachusetts Institute of Technology Sloan School of Management. - Omid Farokhzad，自Senti Biosciences，Inc.业务合并于2022年6月结束以来，一直担任Senti Biosciences，Inc.董事会成员。他于2017年创立了推进变革性蛋白质组学平台的Seer, Inc.（纳斯达克：SEER），并自2018年2月起担任其首席执行官，自2017年3月起担任其董事会成员，自2020年9月起担任主席。他还曾于2021年3月至2022年6月担任Senti Biosciences，Inc.前身Dynamics Special Purpose Corp.（纳斯达克股票代码：DYNS）的创始人、首席执行官兼主席。他此前与人共同创立了BIND Therapeutics（已被辉瑞公司（NYSE：PFE）收购）、Selecta Biosciences, Inc.（纳斯达克：SELB），以及Tarveda Therapeutics，Inc.，一家私营肿瘤生物治疗公司，后者正在开发用于生物制剂和基因治疗的新型抗原特异性耐受平台。2004年9月至2018年2月，任哈佛医学院教授，布莱根妇女医院纳米医学中心主任。Farokhzad博士拥有波士顿大学的硕士和医学博士学位，以及麻省理工学院斯隆管理学院的MBA学位。
- Omid Farokhzad,has served as Chief Executive Officer since February 2018, and as a member of board of directors since March 2017, serving as the Chair since September 2020, and as President of the Company from September 2022 until November 2023. He served as the executive chair of Dynamics Special Purpose Corp., a blank check company, from May 2021 until June 2022. From September 2004 to February 2018, he was a Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women's Hospital. He previously co-founded BIND Therapeutics, a biotechnology company acquired by Pfizer Inc., Selecta Biosciences, Inc., a clinical-stage biotechnology company, and Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company. He currently serves as a member of the board of directors of several privately-held companies and previously served as a director of Senti Biosciences, Selecta Biosciences and BIND Therapeutics. He holds an M.A. and M.D. from Boston University and an M.B.A. from Massachusetts Institute of Technology Sloan School of Management.
- Terrance McGuire
-
Terrance McGuire自2017年12月以来一直担任我们的董事会成员。McGuire先生担任Polaris Partners的普通合伙人，这是一家他于1996年联合创立的风险投资公司。他目前任职于Alector，Inc.和Cyclerion公司的董事会，此前曾任职于Acceleron Pharma公司、Arsanis公司、IronwoodPharmaceuticals，Inc.公司和Pulmatrix，Inc.公司的董事会。McGuire先生还担任麻省理工学院（Massachusetts Institute of Technology）David H.Koch综合癌症研究所的董事会成员，哈佛商学院Arthur Rock创业中心和梦百合倡议咨询委员会以及达特茅斯学院Thayer工程学院顾问委员会。McGuire先生拥有霍巴特学院（Hobart College）的物理学和经济学学士学位，达特茅斯学院（Thayer School at Dartmouth College）的工程学硕士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Terrance McGuire,has served as a member of Board since October 2020. Mr. McGuire was a co-founder and is currently a general partner of Polaris Partners. He currently serves on the boards of directors of Seer, Inc. and Tectonic Therapeutic, Inc., as well as several private companies, including Adimab, LLC. Mr. McGuire previously served on the boards of directors of Alector, Inc., Acceleron Pharma, Inc., Akamai Technologies, Inc., Cubist, Inc., Cyclerion Therapeutics, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr. McGuire is the former chairman of the National Venture Capital Association and a current member of the board of advisors of the Thayer School of Engineering at Dartmouth College. He is a member of the boards of the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr. McGuire is also on the Scientific Advisory Board of the Brigham and Women's Hospital. Mr. McGuire holds a B.S. in physics and economics from Hobart College, an M.S. in engineering from the Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School. - Terrance McGuire自2017年12月以来一直担任我们的董事会成员。McGuire先生担任Polaris Partners的普通合伙人，这是一家他于1996年联合创立的风险投资公司。他目前任职于Alector，Inc.和Cyclerion公司的董事会，此前曾任职于Acceleron Pharma公司、Arsanis公司、IronwoodPharmaceuticals，Inc.公司和Pulmatrix，Inc.公司的董事会。McGuire先生还担任麻省理工学院（Massachusetts Institute of Technology）David H.Koch综合癌症研究所的董事会成员，哈佛商学院Arthur Rock创业中心和梦百合倡议咨询委员会以及达特茅斯学院Thayer工程学院顾问委员会。McGuire先生拥有霍巴特学院（Hobart College）的物理学和经济学学士学位，达特茅斯学院（Thayer School at Dartmouth College）的工程学硕士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Terrance McGuire,has served as a member of Board since October 2020. Mr. McGuire was a co-founder and is currently a general partner of Polaris Partners. He currently serves on the boards of directors of Seer, Inc. and Tectonic Therapeutic, Inc., as well as several private companies, including Adimab, LLC. Mr. McGuire previously served on the boards of directors of Alector, Inc., Acceleron Pharma, Inc., Akamai Technologies, Inc., Cubist, Inc., Cyclerion Therapeutics, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr. McGuire is the former chairman of the National Venture Capital Association and a current member of the board of advisors of the Thayer School of Engineering at Dartmouth College. He is a member of the boards of the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr. McGuire is also on the Scientific Advisory Board of the Brigham and Women's Hospital. Mr. McGuire holds a B.S. in physics and economics from Hobart College, an M.S. in engineering from the Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School.
- Nicolas Roelofs
-
Nicolas Roelofs自2020年12月以来一直担任我们的董事会成员。Roelofs博士自2019年7月起担任Summa Equity AB的负责人。Roelofs博士自2014年以来还担任Nordic Capital的工业顾问。Roelofs博士担任多家私人控股公司的董事会主席，包括Sengenics Corporation Pte Ltd.，One Biomed Pte Ltd.，Scalebio Ltd.和Boreal Genomics Inc.。Roelofs博士还担任多家私人控股公司的董事会成员，包括Hytest Ltd.，The Binding Site Group Ltd.，Insilixa，Inc.和LGC Group。他也是908DevicesInc.的顾问委员会成员Roelofs博士此前曾担任安捷伦科技公司（Agilent Technologies）的生命科学集团总裁，Bio-Rad Inc.生命科学部门的集团运营官，以及Stratagene Inc.的首席运营官。Roelofs博士在辛普森学院（Simpson College）获得化学、生物学和德语理学学士学位，在爱荷华州立大学（Iowa State University）获得有机化学理学硕士学位，在内华达大学里诺分校（University of Nevada，Reno）获得有机化学博士学位。
Nicolas Roelofs has served as a member of our Board of Directors since December 2020. Dr. Roelofs has served as a Principal of Summa Equity AB since July 2019. Dr. Roelofs has also served as Industrial Advisor of Nordic Capital since 2014. Dr. Roelofs serves as chairman of the board of directors of multiple privately-held companies, including Sengenics Corporation Pte Ltd., One BioMed Pte Ltd., ScaleBio Ltd., and Boreal Genomics Inc. Dr. Roelofs also serves as a member of the board of directors of multiple privately-held companies, including HyTest Ltd., The Binding Site Group Ltd., InSilixa, Inc., and LGC Group. He also serves as an advisory board member of 908 Devices Inc. Dr. Roelofs previously served as the President of the Life Sciences Group at Agilent Technologies, Group Operations Officer for the Life Sciences Division of Bio-Rad Inc., and Chief Operating Officer of Stratagene Inc. Dr. Roelofs received his Bachelor of Science in chemistry, biology, and German from Simpson College, his Master of Science in organic chemistry from Iowa State University, and his doctorate in organic chemistry from University of Nevada, Reno. - Nicolas Roelofs自2020年12月以来一直担任我们的董事会成员。Roelofs博士自2019年7月起担任Summa Equity AB的负责人。Roelofs博士自2014年以来还担任Nordic Capital的工业顾问。Roelofs博士担任多家私人控股公司的董事会主席，包括Sengenics Corporation Pte Ltd.，One Biomed Pte Ltd.，Scalebio Ltd.和Boreal Genomics Inc.。Roelofs博士还担任多家私人控股公司的董事会成员，包括Hytest Ltd.，The Binding Site Group Ltd.，Insilixa，Inc.和LGC Group。他也是908DevicesInc.的顾问委员会成员Roelofs博士此前曾担任安捷伦科技公司（Agilent Technologies）的生命科学集团总裁，Bio-Rad Inc.生命科学部门的集团运营官，以及Stratagene Inc.的首席运营官。Roelofs博士在辛普森学院（Simpson College）获得化学、生物学和德语理学学士学位，在爱荷华州立大学（Iowa State University）获得有机化学理学硕士学位，在内华达大学里诺分校（University of Nevada，Reno）获得有机化学博士学位。
- Nicolas Roelofs has served as a member of our Board of Directors since December 2020. Dr. Roelofs has served as a Principal of Summa Equity AB since July 2019. Dr. Roelofs has also served as Industrial Advisor of Nordic Capital since 2014. Dr. Roelofs serves as chairman of the board of directors of multiple privately-held companies, including Sengenics Corporation Pte Ltd., One BioMed Pte Ltd., ScaleBio Ltd., and Boreal Genomics Inc. Dr. Roelofs also serves as a member of the board of directors of multiple privately-held companies, including HyTest Ltd., The Binding Site Group Ltd., InSilixa, Inc., and LGC Group. He also serves as an advisory board member of 908 Devices Inc. Dr. Roelofs previously served as the President of the Life Sciences Group at Agilent Technologies, Group Operations Officer for the Life Sciences Division of Bio-Rad Inc., and Chief Operating Officer of Stratagene Inc. Dr. Roelofs received his Bachelor of Science in chemistry, biology, and German from Simpson College, his Master of Science in organic chemistry from Iowa State University, and his doctorate in organic chemistry from University of Nevada, Reno.
- Meeta Gulyani
-
Meeta Gulyani，自2021年11月起担任董事会成员。Gulyani女士自2024年12月起担任艺康高级副总裁、生物加工部门总经理及生命科学战略负责人。从2023年10月到2024年2月，她是Novo Advisory Group的成员，这是一家管理咨询公司，既帮助健康的公司，也帮助那些面临财务困难的公司。2016年1月至2023年8月，她在德国达姆施塔特默沙东 KGaA生命科学业务部门担任执行副总裁、战略、业务发展和转型主管，该公司是一家全球性生命科学和技术公司，在美国和加拿大以MilliporeSigma的名义运营。2014年5月至2015年12月，她在德国达姆施塔特的默沙东 KGaA制药业务担任执行副总裁、全球战略和特许经营主管，该公司在美国和加拿大以EMD Serono，Inc.的名义运营。2012年1月至2014年4月，Gulyani女士在医疗保健公司Roche Holding AG的分部Roche Pharmaceuticals担任印度管理中心总经理。Gulyani女士目前担任Single Use Support GmbH的顾问委员会成员。Gulyani女士拥有菲律宾亚洲管理学院的工商管理硕士学位，并伴随着宾夕法尼亚大学沃顿商学院的交流项目。她获得了印度德里大学Shri Ram商业学院的经济学学士学位。
Meeta Gulyani,has served as a member of board of directors since November 2021. Ms. Gulyani has served as Senior Vice President, General Manager, Bioprocessing and Head of Life Science Strategy of Ecolab, since December 2024. From October 2023 to February 2024, she was a member of Novo Advisory Group, a management advisory firm assisting both healthy companies and those facing financial difficulty. From January 2016 to August 2023, she served as Executive Vice President, Head of Strategy, Business Development and Transformation at the Life Science business of Merck KGaA, Darmstadt, Germany, a global life science and technology company, which operates as MilliporeSigma in U.S. and Canada. From May 2014 to December 2015, she served as Executive Vice President, Head of Global Strategy and Franchises at the Pharmaceutical business of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono, Inc. in U.S. and Canada. From January 2012 to April 2014, Ms. Gulyani served as General Manager, India Management Center at Roche Pharmaceuticals, division of Roche Holding AG, a healthcare company. Ms. Gulyani currently serves as an advisory board member of Single Use Support GmbH. Ms. Gulyani holds a M.B.A. from the Asian Institute of Management, Philippines, accompanied by an exchange program at the Wharton School of the University of Pennsylvania. She earned a bachelor's degree in economics from the Shri Ram College of Commerce at Delhi University in India. - Meeta Gulyani，自2021年11月起担任董事会成员。Gulyani女士自2024年12月起担任艺康高级副总裁、生物加工部门总经理及生命科学战略负责人。从2023年10月到2024年2月，她是Novo Advisory Group的成员，这是一家管理咨询公司，既帮助健康的公司，也帮助那些面临财务困难的公司。2016年1月至2023年8月，她在德国达姆施塔特默沙东 KGaA生命科学业务部门担任执行副总裁、战略、业务发展和转型主管，该公司是一家全球性生命科学和技术公司，在美国和加拿大以MilliporeSigma的名义运营。2014年5月至2015年12月，她在德国达姆施塔特的默沙东 KGaA制药业务担任执行副总裁、全球战略和特许经营主管，该公司在美国和加拿大以EMD Serono，Inc.的名义运营。2012年1月至2014年4月，Gulyani女士在医疗保健公司Roche Holding AG的分部Roche Pharmaceuticals担任印度管理中心总经理。Gulyani女士目前担任Single Use Support GmbH的顾问委员会成员。Gulyani女士拥有菲律宾亚洲管理学院的工商管理硕士学位，并伴随着宾夕法尼亚大学沃顿商学院的交流项目。她获得了印度德里大学Shri Ram商业学院的经济学学士学位。
- Meeta Gulyani,has served as a member of board of directors since November 2021. Ms. Gulyani has served as Senior Vice President, General Manager, Bioprocessing and Head of Life Science Strategy of Ecolab, since December 2024. From October 2023 to February 2024, she was a member of Novo Advisory Group, a management advisory firm assisting both healthy companies and those facing financial difficulty. From January 2016 to August 2023, she served as Executive Vice President, Head of Strategy, Business Development and Transformation at the Life Science business of Merck KGaA, Darmstadt, Germany, a global life science and technology company, which operates as MilliporeSigma in U.S. and Canada. From May 2014 to December 2015, she served as Executive Vice President, Head of Global Strategy and Franchises at the Pharmaceutical business of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono, Inc. in U.S. and Canada. From January 2012 to April 2014, Ms. Gulyani served as General Manager, India Management Center at Roche Pharmaceuticals, division of Roche Holding AG, a healthcare company. Ms. Gulyani currently serves as an advisory board member of Single Use Support GmbH. Ms. Gulyani holds a M.B.A. from the Asian Institute of Management, Philippines, accompanied by an exchange program at the Wharton School of the University of Pennsylvania. She earned a bachelor's degree in economics from the Shri Ram College of Commerce at Delhi University in India.
- Isaac Ro
-
艾萨克·罗（Isaac Ro）是Catalio Capital Management的合伙人，在该公司领导了对突破性生命科学公司的多项风险投资和私人信贷投资。他目前在PinkDX和PrognomiQ的董事会任职。此前，他是Haystack Oncology的执行主席，在那里他带领该公司在2023年被奎斯特诊疗成功收购。在加入Catalio之前，Ro先生曾担任Sema4（NASDAQ：WGS）的首席财务官，在那里他指导该公司完成了2021年的公开上市以及对GeneDX的收购。他还曾担任Thrive Early Detection的首席财务官，在那里他领导了该公司的发布以及随后在2020年出售给精密科学。在Thrive之前，Ro先生曾于2010年至2019年在高盛 Sachs领导美国医疗技术和生命科学工具股票研究团队，在此之前曾在Leerink Partners担任类似职务。罗先生获得了历史学学士学位，并在米德尔伯里学院获得了医学预科学位。
Isaac Ro,is a Partner at Catalio Capital Management, where he has led multiple venture and private credit investments in breakthrough life science companies. He currently serves on the boards of PinkDx and PrognomiQ. Previously, he was Executive Chairman of Haystack Oncology, where he led the company through its successful acquisition by Quest Diagnostics in 2023. Prior to Catalio, Mr. Ro served as Chief Financial Officer of Sema4 (NASDAQ: WGS), where he guided the company through its public listing in 2021 and the acquisition of GeneDx. He also held the role of Chief Financial Officer of Thrive Earlier Detection, where he led the company's launch and subsequent sale to Exact Sciences in 2020. Prior to Thrive, Mr. Ro led the U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs from 2010 to 2019, and held a similar role at Leerink Partners prior to that. Mr. Ro earned his B.A. in History and was Pre-Med at Middlebury College. - 艾萨克·罗（Isaac Ro）是Catalio Capital Management的合伙人，在该公司领导了对突破性生命科学公司的多项风险投资和私人信贷投资。他目前在PinkDX和PrognomiQ的董事会任职。此前，他是Haystack Oncology的执行主席，在那里他带领该公司在2023年被奎斯特诊疗成功收购。在加入Catalio之前，Ro先生曾担任Sema4（NASDAQ：WGS）的首席财务官，在那里他指导该公司完成了2021年的公开上市以及对GeneDX的收购。他还曾担任Thrive Early Detection的首席财务官，在那里他领导了该公司的发布以及随后在2020年出售给精密科学。在Thrive之前，Ro先生曾于2010年至2019年在高盛 Sachs领导美国医疗技术和生命科学工具股票研究团队，在此之前曾在Leerink Partners担任类似职务。罗先生获得了历史学学士学位，并在米德尔伯里学院获得了医学预科学位。
- Isaac Ro,is a Partner at Catalio Capital Management, where he has led multiple venture and private credit investments in breakthrough life science companies. He currently serves on the boards of PinkDx and PrognomiQ. Previously, he was Executive Chairman of Haystack Oncology, where he led the company through its successful acquisition by Quest Diagnostics in 2023. Prior to Catalio, Mr. Ro served as Chief Financial Officer of Sema4 (NASDAQ: WGS), where he guided the company through its public listing in 2021 and the acquisition of GeneDx. He also held the role of Chief Financial Officer of Thrive Earlier Detection, where he led the company's launch and subsequent sale to Exact Sciences in 2020. Prior to Thrive, Mr. Ro led the U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs from 2010 to 2019, and held a similar role at Leerink Partners prior to that. Mr. Ro earned his B.A. in History and was Pre-Med at Middlebury College.
- Dipchand Nishar
-
Dipchand Nishar自2011年1月开始担任产品和用户体验高级副总裁；2009年1月到2011年1月期间，担任公司产品副总裁。在加入Linkedln之前，Nishar先生曾担任过一些职位，包括最近的在2003年8月到2009年1月期间在谷歌公司（一家互联网搜索公司）担任亚太地区的产品高级主管。他还曾是Patkai Networks（一家面向服务的体系结构软件公司）的创始人和产品副总裁。Nishar先生目前在TripAdvisor（一家基于互联网的旅游景点和信息供应商）以及Opower, Inc.（一家面向实体行业的云集软件供应商）的董事会任职。Nishar先生拥有哈佛商学院的工商管理硕士学位，曾获得哈佛大学最高荣誉Baker奖学金，还拥有伊利诺伊大学香槟分校的M.SEE以及印度技术大学的B.Tech。
Dipchand Nishar has served as a member of board of directors since June 2019. Since June 2015 Mr. Nishar has worked for SoftBank Investment Advisors and currently serves as Senior Managing Partner. From August 2003 to January 2009 Mr. Nishar served in various roles with Google Inc., most recently as the Senior Director of Products for the Asia-Pacific region. In addition, during the past five years, Mr. Nishar has served as a member of the board of directors of various publicly traded companies, including Guardant Health, Inc., Vir Biotechnology, Inc., TripAdvisor, Inc., and OPower, Inc. Mr. Nishar holds a B. Tech from the Indian Institute of Technology, a MSEE from the University of Illinois, Urbana-Champaign, and a MBA from the Harvard Business School. - Dipchand Nishar自2011年1月开始担任产品和用户体验高级副总裁；2009年1月到2011年1月期间，担任公司产品副总裁。在加入Linkedln之前，Nishar先生曾担任过一些职位，包括最近的在2003年8月到2009年1月期间在谷歌公司（一家互联网搜索公司）担任亚太地区的产品高级主管。他还曾是Patkai Networks（一家面向服务的体系结构软件公司）的创始人和产品副总裁。Nishar先生目前在TripAdvisor（一家基于互联网的旅游景点和信息供应商）以及Opower, Inc.（一家面向实体行业的云集软件供应商）的董事会任职。Nishar先生拥有哈佛商学院的工商管理硕士学位，曾获得哈佛大学最高荣誉Baker奖学金，还拥有伊利诺伊大学香槟分校的M.SEE以及印度技术大学的B.Tech。
- Dipchand Nishar has served as a member of board of directors since June 2019. Since June 2015 Mr. Nishar has worked for SoftBank Investment Advisors and currently serves as Senior Managing Partner. From August 2003 to January 2009 Mr. Nishar served in various roles with Google Inc., most recently as the Senior Director of Products for the Asia-Pacific region. In addition, during the past five years, Mr. Nishar has served as a member of the board of directors of various publicly traded companies, including Guardant Health, Inc., Vir Biotechnology, Inc., TripAdvisor, Inc., and OPower, Inc. Mr. Nishar holds a B. Tech from the Indian Institute of Technology, a MSEE from the University of Illinois, Urbana-Champaign, and a MBA from the Harvard Business School.
- David Hallal
-
David Hallal，自合并完成后一直担任Kalaris Therapeutics，Inc.董事会主席。在合并完成之前，Hallal先生于2021年5月至合并完成前担任Kalaris Therapeutics，Inc.执行董事长，此前曾于2018年9月至2021年5月担任Kalaris Therapeutics，Inc.首席执行官兼董事长。Hallal先生自2025年4月起担任上市公司Scholar Rock Holding公司的首席执行官，并自2017年7月起担任Scholar Rock Holding公司的董事会主席。Hallal先生担任ElevateBio的执行董事长，自2017年12月起，他担任ElevateBio的董事长、首席执行官和联合创始人，该公司是他与他人共同创立的。Hallal先生还担任iTeos Therapeutics SA（一家上市公司）的董事会主席。Halal先生还曾于2018年2月至2025年5月担任上市公司Seer Biosciences，Inc.的董事会成员。在此之前，从2006年6月至2016年12月，Hallal先生在亚力兄制药公司（Alexion Pharmaceuticals，Inc.）或Alexion（一家上市公司）担任越来越重要的高管职务，最近担任首席执行官和董事会成员。在担任首席执行官之前，Hallal先生曾在Alexion担任首席运营官和董事以及首席商务官和商业运营主管。在加入Alexion之前，2004年至2006年，Hallal先生担任OSI Eyetech，Inc.的销售副总裁。2002年至2004年，Hallal先生在上市公司Biogen Inc.担任销售主管。从1992年到2002年，Hallal先生在上市公司安进公司担任过各种领导职务。从1988年到1992年，Hallal先生在Upjohn公司开始了他的制药生涯，担任销售代表。Hallal先生拥有新罕布什尔大学心理学学士学位。
David Hallal,has served as a member of board of directors since February 2018 and as Lead Independent Director from September 2020 to August 2024. Mr. Hallal has served as Chief Executive Officer of ElevateBio LLC, a biotechnology company he co-founded, since December 2017. Mr. Hallal had served as Chief Executive Officer of AlloVir, Inc., a late clinical-stage cell therapy company from September 2018 to March 2021. Prior to that, from June 2006 to December 2016, Mr. Hallal served in executive roles of increasing responsibility at Alexion Pharmaceuticals, Inc., a pharmaceutical company, most recently serving as Chief Executive Officer from April 2015 to December 2016, Chief Operating Officer from September 2014 to April 2015 and Chief Commercial Officer, Head of Commercial Operations from July 2006 to September 2014, as well as a member of the Board of Directors from September 2014 to December 2016. Mr. Hallal currently serves as Chairman of the board at AlloVir, ElevateBio, Scholar Rock Holding Corp. and iTeos Therapeutics S.A. He holds a B.A. in Psychology from the University of New Hampshire. - David Hallal，自合并完成后一直担任Kalaris Therapeutics，Inc.董事会主席。在合并完成之前，Hallal先生于2021年5月至合并完成前担任Kalaris Therapeutics，Inc.执行董事长，此前曾于2018年9月至2021年5月担任Kalaris Therapeutics，Inc.首席执行官兼董事长。Hallal先生自2025年4月起担任上市公司Scholar Rock Holding公司的首席执行官，并自2017年7月起担任Scholar Rock Holding公司的董事会主席。Hallal先生担任ElevateBio的执行董事长，自2017年12月起，他担任ElevateBio的董事长、首席执行官和联合创始人，该公司是他与他人共同创立的。Hallal先生还担任iTeos Therapeutics SA（一家上市公司）的董事会主席。Halal先生还曾于2018年2月至2025年5月担任上市公司Seer Biosciences，Inc.的董事会成员。在此之前，从2006年6月至2016年12月，Hallal先生在亚力兄制药公司（Alexion Pharmaceuticals，Inc.）或Alexion（一家上市公司）担任越来越重要的高管职务，最近担任首席执行官和董事会成员。在担任首席执行官之前，Hallal先生曾在Alexion担任首席运营官和董事以及首席商务官和商业运营主管。在加入Alexion之前，2004年至2006年，Hallal先生担任OSI Eyetech，Inc.的销售副总裁。2002年至2004年，Hallal先生在上市公司Biogen Inc.担任销售主管。从1992年到2002年，Hallal先生在上市公司安进公司担任过各种领导职务。从1988年到1992年，Hallal先生在Upjohn公司开始了他的制药生涯，担任销售代表。Hallal先生拥有新罕布什尔大学心理学学士学位。
- David Hallal,has served as a member of board of directors since February 2018 and as Lead Independent Director from September 2020 to August 2024. Mr. Hallal has served as Chief Executive Officer of ElevateBio LLC, a biotechnology company he co-founded, since December 2017. Mr. Hallal had served as Chief Executive Officer of AlloVir, Inc., a late clinical-stage cell therapy company from September 2018 to March 2021. Prior to that, from June 2006 to December 2016, Mr. Hallal served in executive roles of increasing responsibility at Alexion Pharmaceuticals, Inc., a pharmaceutical company, most recently serving as Chief Executive Officer from April 2015 to December 2016, Chief Operating Officer from September 2014 to April 2015 and Chief Commercial Officer, Head of Commercial Operations from July 2006 to September 2014, as well as a member of the Board of Directors from September 2014 to December 2016. Mr. Hallal currently serves as Chairman of the board at AlloVir, ElevateBio, Scholar Rock Holding Corp. and iTeos Therapeutics S.A. He holds a B.A. in Psychology from the University of New Hampshire.
- Robert Langer
-
Robert Langer，自2005年起担任麻省理工学院教授，在此之前，自1977年起担任麻省理工学院教授。从1995年到2002年，他担任美国食品和药物管理局科学委员会成员，包括四年的主席。他是美国国家科学院、美国国家工程院和美国国家医学院的当选成员。
Robert Langer,has served as a member of board of directors since December 2017. Dr. Langer has served as an Institute Professor at the Massachusetts Institute of Technology since July 2005. He currently serves on the board of directors of Abpro Bio Co. Ltd., Frequency Therapeutics, Inc., and Puretech Health plc, and previously served on the board of directors of Alkermes, Inc., Lyra Therapeutics, Inc., Kala Pharmaceuticals, Inc., Moderna, Inc., Momenta Pharmaceuticals, Inc., Millipore Corp., Rubius Therapeutics and Wyeth. Dr. Langer currently serves on the Board of Trustees at Boston Children's Hospital. Dr. Langer holds a B.S. in Chemical Engineering from Cornell University and an Sc.D. in Chemical Engineering from Massachusetts Institute of Technology. - Robert Langer，自2005年起担任麻省理工学院教授，在此之前，自1977年起担任麻省理工学院教授。从1995年到2002年，他担任美国食品和药物管理局科学委员会成员，包括四年的主席。他是美国国家科学院、美国国家工程院和美国国家医学院的当选成员。
- Robert Langer,has served as a member of board of directors since December 2017. Dr. Langer has served as an Institute Professor at the Massachusetts Institute of Technology since July 2005. He currently serves on the board of directors of Abpro Bio Co. Ltd., Frequency Therapeutics, Inc., and Puretech Health plc, and previously served on the board of directors of Alkermes, Inc., Lyra Therapeutics, Inc., Kala Pharmaceuticals, Inc., Moderna, Inc., Momenta Pharmaceuticals, Inc., Millipore Corp., Rubius Therapeutics and Wyeth. Dr. Langer currently serves on the Board of Trustees at Boston Children's Hospital. Dr. Langer holds a B.S. in Chemical Engineering from Cornell University and an Sc.D. in Chemical Engineering from Massachusetts Institute of Technology.
高管简历
中英对照 | 中文 | 英文- Omid Farokhzad
Omid Farokhzad，自Senti Biosciences，Inc.业务合并于2022年6月结束以来，一直担任Senti Biosciences，Inc.董事会成员。他于2017年创立了推进变革性蛋白质组学平台的Seer, Inc.（纳斯达克：SEER），并自2018年2月起担任其首席执行官，自2017年3月起担任其董事会成员，自2020年9月起担任主席。他还曾于2021年3月至2022年6月担任Senti Biosciences，Inc.前身Dynamics Special Purpose Corp.（纳斯达克股票代码：DYNS）的创始人、首席执行官兼主席。他此前与人共同创立了BIND Therapeutics（已被辉瑞公司（NYSE：PFE）收购）、Selecta Biosciences, Inc.（纳斯达克：SELB），以及Tarveda Therapeutics，Inc.，一家私营肿瘤生物治疗公司，后者正在开发用于生物制剂和基因治疗的新型抗原特异性耐受平台。2004年9月至2018年2月，任哈佛医学院教授，布莱根妇女医院纳米医学中心主任。Farokhzad博士拥有波士顿大学的硕士和医学博士学位，以及麻省理工学院斯隆管理学院的MBA学位。
Omid Farokhzad,has served as Chief Executive Officer since February 2018, and as a member of board of directors since March 2017, serving as the Chair since September 2020, and as President of the Company from September 2022 until November 2023. He served as the executive chair of Dynamics Special Purpose Corp., a blank check company, from May 2021 until June 2022. From September 2004 to February 2018, he was a Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women's Hospital. He previously co-founded BIND Therapeutics, a biotechnology company acquired by Pfizer Inc., Selecta Biosciences, Inc., a clinical-stage biotechnology company, and Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company. He currently serves as a member of the board of directors of several privately-held companies and previously served as a director of Senti Biosciences, Selecta Biosciences and BIND Therapeutics. He holds an M.A. and M.D. from Boston University and an M.B.A. from Massachusetts Institute of Technology Sloan School of Management.- Omid Farokhzad，自Senti Biosciences，Inc.业务合并于2022年6月结束以来，一直担任Senti Biosciences，Inc.董事会成员。他于2017年创立了推进变革性蛋白质组学平台的Seer, Inc.（纳斯达克：SEER），并自2018年2月起担任其首席执行官，自2017年3月起担任其董事会成员，自2020年9月起担任主席。他还曾于2021年3月至2022年6月担任Senti Biosciences，Inc.前身Dynamics Special Purpose Corp.（纳斯达克股票代码：DYNS）的创始人、首席执行官兼主席。他此前与人共同创立了BIND Therapeutics（已被辉瑞公司（NYSE：PFE）收购）、Selecta Biosciences, Inc.（纳斯达克：SELB），以及Tarveda Therapeutics，Inc.，一家私营肿瘤生物治疗公司，后者正在开发用于生物制剂和基因治疗的新型抗原特异性耐受平台。2004年9月至2018年2月，任哈佛医学院教授，布莱根妇女医院纳米医学中心主任。Farokhzad博士拥有波士顿大学的硕士和医学博士学位，以及麻省理工学院斯隆管理学院的MBA学位。
- Omid Farokhzad,has served as Chief Executive Officer since February 2018, and as a member of board of directors since March 2017, serving as the Chair since September 2020, and as President of the Company from September 2022 until November 2023. He served as the executive chair of Dynamics Special Purpose Corp., a blank check company, from May 2021 until June 2022. From September 2004 to February 2018, he was a Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women's Hospital. He previously co-founded BIND Therapeutics, a biotechnology company acquired by Pfizer Inc., Selecta Biosciences, Inc., a clinical-stage biotechnology company, and Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company. He currently serves as a member of the board of directors of several privately-held companies and previously served as a director of Senti Biosciences, Selecta Biosciences and BIND Therapeutics. He holds an M.A. and M.D. from Boston University and an M.B.A. from Massachusetts Institute of Technology Sloan School of Management.
- David R. Horn
David R.Horn自2020年5月起担任我们的首席财务官。在加入我们之前，霍恩先生于2007年5月至2020年5月在投资银行和金融服务公司摩根士丹利任职，在那里他曾担任投资银行部全球梦百合集团的董事总经理。从2003年5月到2007年5月，Horn先生担任Montgomery&Co.，LLC的负责人，这是一家并购与私募服务提供商。他持有Princeton University的政治学士学位，以及Stanford University Graduate School of Business的工商管理硕士学位。
David R. Horn has served as our Chief Financial Officer since May 2020. Prior to joining us, Mr. Horn was with Morgan Stanley, an investment bank and financial services company, from May 2007 to May 2020 where he served as a Managing Director in the Global Healthcare Group within the Investment Banking Department. From May 2003 to May 2007 Mr. Horn served as a Principal at Montgomery & Co., LLC, a provider of merger and acquisition and private placement services. He holds an A.B. in Politics from Princeton University and an M.B.A. from Stanford University Graduate School of Business.- David R.Horn自2020年5月起担任我们的首席财务官。在加入我们之前，霍恩先生于2007年5月至2020年5月在投资银行和金融服务公司摩根士丹利任职，在那里他曾担任投资银行部全球梦百合集团的董事总经理。从2003年5月到2007年5月，Horn先生担任Montgomery&Co.，LLC的负责人，这是一家并购与私募服务提供商。他持有Princeton University的政治学士学位，以及Stanford University Graduate School of Business的工商管理硕士学位。
- David R. Horn has served as our Chief Financial Officer since May 2020. Prior to joining us, Mr. Horn was with Morgan Stanley, an investment bank and financial services company, from May 2007 to May 2020 where he served as a Managing Director in the Global Healthcare Group within the Investment Banking Department. From May 2003 to May 2007 Mr. Horn served as a Principal at Montgomery & Co., LLC, a provider of merger and acquisition and private placement services. He holds an A.B. in Politics from Princeton University and an M.B.A. from Stanford University Graduate School of Business.